Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones

Journal of Inherited Metabolic Disease

Volumn 33, Issue 1, 2010, Pages 61-67

  Arfi, Audrey ^a,b,c,d   Richard, Magali ^a,b,c,d   Gandolphe, Christelle ^a,b,c,d   Scherman, Daniel ^a,b,c,d  

^a INSERM   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d PSL RESEARCH UNIVERSITY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHANIN A; DAIDZEIN; FORMONONETIN; GENISTEIN; GLYCITEIN; GLYCOSAMINOGLYCAN; ISOFLAVONE DERIVATIVE; PRUNETIN;

ARTICLE; CELL LINE; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG USE; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; MUCOPOLYSACCHARIDOSIS TYPE 7; SANFILIPPO SYNDROME; SANFILIPPO SYNDROME TYPE A; TOXICITY TESTING;

BONE MARROW TRANSPLANTATION; CHONDROITIN SULFATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROBLASTS; GENISTEIN; GLYCOSAMINOGLYCANS; HUMANS; ISOFLAVONES; LYSOSOMES; MODELS, BIOLOGICAL; MODELS, CHEMICAL; MUCOPOLYSACCHARIDOSIS III; MUCOPOLYSACCHARIDOSIS VII; TETRAZOLIUM SALTS; THIAZOLES;

EID: 77649235699     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-009-9029-2     Document Type: Article

References (35)

1. M Beck 2007 New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy Hum Genet 121 1 1 22 10.1007/s00439-006-0280-4 1:CAS:528:DC%2BD2sXhsFCgs7k%3D 17089160 (Pubitemid 46421136)
2. LT Bloedon AR Jeffcoat W Lopaczynski, et al. 2002 Safety and pharmacokinetics of purified soy isoflavones: single-dose administration to postmenopausal women Am J Clin Nutr 76 5 1126 1137 1:CAS:528: DC%2BD38XosF2qsLg%3D 12399289
3. DA Brooks VJ Muller JJ Hopwood 2006 Stop-codon read-through for patients affected by a lysosomal storage disorder Trends Mol Med 12 8 367 373 10.1016/j.molmed.2006.06.001 1:CAS:528:DC%2BD28XotVCktLc%3D 16798086 (Pubitemid 44149238)
4. MG Busby AR Jeffcoat LT Bloedon, et al. 2002 Clinical characteristics and pharmacokinetics of purified soy isoflavones: single-dose administration to healthy men Am J Clin Nutr 75 1 126 136 1:CAS:528:DC%2BD38XhslylsQ%3D%3D 11756070
5. MA Cleary JE Wraith 1993 Management of mucopolysaccharidosis type III Arch Dis Child 69 403 406 10.1136/adc.69.3.403 1:STN:280:DyaK2c%2FivFWgsA%3D%3D 8215557
6. TM Cox 2005 Substrate reduction therapy for lysosomal storage diseases Acta Paediatr Suppl 94 447 69 75 10.1080/08035320510028157 1:STN:280: DC%2BD2M3lsFSiuw%3D%3D 15895716
7. L Fischer C Mahoney AR Jeffcoat, et al. 2004 Clinical characteristics and pharmacokinetics of purified soy isoflavones: multiple-dose administration to men with prostate neoplasia Nutr Cancer 48 2 160 170 10.1207/s15327914nc4802-5 1:CAS:528:DC%2BD2cXmslGqtrk%3D 15231450
8. R Handayani L Rice Y Cui, et al. 2006 Soy isoflavones alter expression of genes associated with cancer progression, including interleukin-8, in androgen-independent PC-3 human prostate cancer cells J Nutr 136 1 75 82 1:CAS:528:DC%2BD28XivFSnsw%3D%3D 16365062
9. Harmatz P, Giugliani R, Schwartz I, et al, MPS VI Phase 3 Study Group 2006 Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study J Pediatr 148 4 533 539 10.1016/j.jpeds.2005.12.014 (Pubitemid 44419350)
10. J Jakóbkiewicz-Banecka A Wegrzyn G Wegrzyn 2007 Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases J Appl Genet 48 4 383 388 17998597
11. J Jakóbkiewicz-Banecka E Piotrowska M Narajczyk S Barańska G Wegrzyn 2009 Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway J Biomed Sci 16 26 10.1186/1423-0127-16-26 19272193
12. ED Kakkis J Muenzer GE Tiller, et al. 2001 Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344 3 182 188 10.1056/NEJM200101183440304 1:CAS:528:DC%2BD3MXosleksw%3D%3D (Pubitemid 32064139)
13. M Malinowska FL Wilkinson W Bennett, et al. 2009 Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice Mol Genet Metab 98 3 235 242 10.1016/j.ymgme.2009.06.013 1:CAS:528: DC%2BD1MXht1GmtLrL 19632871
14. R Michael McClain E Wolz A Davidovich J Bausch 2005 Genetic toxicity studies with genistein Food Chem Toxicol 44 1 42 55 16198038
15. W Miltyk CN Craciunescu L Fischer, et al. 2003 Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer Am J Clin Nutr 77 4 875 882 1:CAS:528:DC%2BD3sXnsVSrtrw%3D 12663286
16. J Muenzer JC Lamsa A Garcia J Dacosta J Garcia DA Treco 2002 Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report Acta Paediatr Suppl 91 439 98 99 10.1080/080352502762458012 1:STN:280:DC%2BD3s%2Fmt1Wntw%3D%3D 12572850
17. J Muenzer JE Wraith M Beck, et al. 2006 A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) Genet Med 8 8 465 473 10.1097/01.gim.0000232477.37660.fb 1:CAS:528:DC%2BD28XotFWqs7c%3D 16912578 (Pubitemid 44239134)
18. Neufeld E, Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3421-3452
19. RJ Nijveldt E van Nood DE van Hoorn PG Boelens K van Norren PA van Leeuwen 2001 Flavonoids: a review of probable mechanisms of action and potential applications Am J Clin Nutr 74 4 418 425 1:CAS:528:DC%2BD3MXnt1Cksro%3D 11566638
20. GM Pastores S Sathe 2006 A chaperone-mediated approach to enzyme enhancement as a therapeutic option for the lysosomal storage disorders Drugs R D 7 6 339 348 10.2165/00126839-200607060-00003 1:CAS:528:DC%2BD2sXls1aiug%3D%3D 17073517 (Pubitemid 44672800)
21. D Pelled T Raveh C Riebeling M Fridkin H Berissi AH Futerman A Kimchi 2002 Death-associated protein (DAP) kinase plays a central role in ceramide-induced apoptosis in cultured hippocampal neurons J Biol Chem 277 3 1957 1961 10.1074/jbc.M104677200 1:CAS:528:DC%2BD38XosFensg%3D%3D 11709549 (Pubitemid 34968774)
22. E Piotrowska J Jakóbkiewicz-Banecka S Barańska A Tylki-Szymańska B Czartoryska A Wegrzyn G Wegrzyn 2006 Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses Eur J Hum Genet 14 7 846 852 10.1038/sj.ejhg.5201623 1:CAS:528:DC%2BD28XmtVSmtrw%3D 16670689 (Pubitemid 43923370)
23. E Piotrowska J Jakóbkiewicz-Banecka A Tylki-Szymanska A Libereck A Maryaniak M Malinowska B Czartoryska E Puk A Kloska T Libereck S Barańska A Wegrzyn G Wegrzyn 2008 Genistein-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo Syndrome: an open-label, pilot study in 10 pediatric patients Curr Ther Res 69 2 166 179 10.1016/j.curtheres. 2008.04.002 1:CAS:528:DC%2BD1cXnsFOmtLo%3D (Pubitemid 351834736)
24. Piotrowska E, Jakóbkiewicz-Banecka J, Wegrzyn G (2009) Different amounts of isoflavones in various commercially available soy extracts in the light of gene expression-targeted isoflavone therapy. Phytother Res [Epub ahead of print].
25. R Raman S Raguram G Venkataraman JC Paulson R Sasisekharan 2005 Glycomics: an integrated systems approach to structure-function relationships of glycans Nat Methods 2 11 817 824 10.1038/nmeth807 1:CAS:528:DC%2BD2MXhtFyrtbzL 16278650 (Pubitemid 41741530)
26. M Richard A Arfi H Rhinn C Gandolphe D Scherman 2008 Identification of new markers for neurodegeneration process in the mouse model of Sly disease as revealed by expression profiling of selected genes J Neurosci Res 86 15 3285 3294 10.1002/jnr.21779 1:CAS:528:DC%2BD1cXhsVaru77N 18646207
27. M Richard A Arfi J Seguin C Gandolphe D Scherman 2009 Widespread biochemical correction of murine mucopolysaccharidosis type VII pathology by liver hydrodynamic plasmid delivery Gene Ther 16 6 746 756 10.1038/gt.2009.36 1:CAS:528:DC%2BD1MXkt1Srt70%3D 19357715
28. C Settembre A Fraldi L Jahreiss, et al. 2008 A block of autophagy in lysosomal storage disorders Hum Mol Genet 17 1 119 129 10.1093/hmg/ddm289 1:CAS:528:DC%2BD2sXhsVKiur%2FK 17913701
29. WS Sly BA Quinton WH McAlister DL Rimoin 1973 Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis J Pediatr 82 2 249 257 10.1016/S0022-3476(73)80162-3 1:STN:280:DyaE3s%2FosFSkuw%3D%3D 4265197
30. S Tomatsu AM Montaño A Ohashi, et al. 2008 Enzyme replacement therapy in a murine model of Morquio A syndrome Hum Mol Genet 17 6 815 824 10.1093/hmg/ddm353 1:CAS:528:DC%2BD1cXis1Gltb8%3D 18056156 (Pubitemid 351359698)
31. TH Tsai 2005 Concurrent measurement of unbound genistein in the blood, brain and bile of anesthetized rats using microdialysis and its pharmacokinetic application J Chromatogr A 1073 317 322 10.1016/j.chroma.2004.10.048 1:CAS:528:DC%2BD2MXjsVegt74%3D 15909536 (Pubitemid 40544505)
32. U Ullmann H Oberwittle M Grossmann C Riegger 2005 Repeated oral once daily intake of increasing doses of the novel synthetic genistein product Bonistein in healthy volunteers Planta Med 71 10 891 896 10.1055/s-2005-864186 1:CAS:528:DC%2BD2MXht1KgtLbE 16254818 (Pubitemid 41658563)
33. MJ Valstar GJ Ruijter OP van Diggelen BJ Poorthuis FA Wijburg 2008 Sanfilippo syndrome: a mini-review J Inherit Metabol Dis 31 2 240 252 10.1007/s10545-008-0838-5 1:CAS:528:DC%2BD1cXltFequ7Y%3D
34. JE Wraith 2005 The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I Expert Opin Pharmacother 6 3 489 506 10.1517/14656566.6.3.489 1:CAS:528:DC%2BD2MXjvVyrtrk%3D 15794739 (Pubitemid 40521085)
35. JE Wraith LA Clarke M Beck, et al. 2004 Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase) J Pediatr 144 5 581 588 10.1016/j.jpeds.2004.01.046 1:CAS:528:DC%2BD2cXjs1Wnsbg%3D 15126990 (Pubitemid 38594757)